AVIR SEC Filings - Atea Pharmaceuticals, Inc. 10-K, 10-Q, 8-K Forms
This page provides a comprehensive resource for investors and traders to access Atea Pharmaceuticals' (AVIR) official regulatory documents, including 10-K, 10-Q, 8-K forms, and insider trading filings. It details recent filings such as a Form 4 disclosing a stock option grant to director Howard Berman and an 8-K summarizing the 2025 Annual Meeting results where directors were re-elected and auditor ratification and say-on-pay proposals were approved. The platform offers AI-generated summaries, impact scoring, and sentiment analysis for each filing.
Atea Pharmaceuticals director Polly Murphy buys $25,446 in stock
Polly A. Murphy, a director at Atea Pharmaceuticals, Inc. (NASDAQ:AVIR), purchased 6,100 shares of the company’s common stock for $25,446 on May 18, 2026. This transaction increased her direct holdings to 92,145 shares. The purchase comes as the company continues to focus on its strong cash reserves and strategic plans for its Hepatitis C and E programs despite a recent slight miss on Q1 2026 EPS.
Atea Pharmaceuticals (AVIR) director buys 6,100 shares of stock
Atea Pharmaceuticals director Polly A. Murphy purchased 6,100 shares of Common Stock on the open market at a weighted average price of $4.1715 per share on May 18, 2026. This transaction increased her direct ownership to 92,145 shares. The filing, an amended Form 4/A, corrected the transaction date from May 18, 2025, to May 18, 2026.
Atea (AVIR) director adds 6,100 shares in open-market purchase
Atea Pharmaceuticals Director Polly A. Murphy purchased 6,100 shares of common stock on May 18, 2025, through an open-market transaction. The shares were acquired at a weighted average price of $4.1715 per share, ranging from $4.14 to $4.19. Following this acquisition, Murphy directly holds 92,145 shares of the company's common stock, reflecting a neutral filing impact and positive sentiment.
Earnings call transcript: Atea Pharmaceuticals Q1 2026 reveals stock plunge after EPS miss
Atea Pharmaceuticals reported Q1 2026 earnings, missing EPS forecasts by $0.01 with an EPS of -$0.57. This unexpected miss caused the stock to plunge 15.53% in after-hours trading. Despite the setback, the company highlighted a strong cash position of $256 million, providing a runway through 2027, and remains committed to advancing its Hepatitis C and E programs with key milestones expected.
Earnings call transcript: Atea Pharmaceuticals Q1 2026 reveals stock plunge after EPS miss
Atea Pharmaceuticals reported a Q1 2026 EPS of -$0.57, missing the forecast of -$0.56, which led to a 15.53% drop in stock price during after-hours trading. Despite the miss, the company maintains a strong cash position of $256 million, expected to last through 2027, and is focusing on its Hepatitis C Phase III program and a new Hepatitis E program. Key milestones for HCV and HEV programs are anticipated within existing cash resources, with a generally positive outlook from Wall Street analysts.
Atea Pharmaceuticals to Present Three Abstracts at EASL 2026 Congress Highlighting Progress Across Viral Hepatitis Pipeline
Atea Pharmaceuticals announced that three abstracts have been accepted for presentation at the European Association for the Study of the Liver (EASL) Congress 2026. The presentations will include new clinical study results supporting their fixed-dose combination of bemnifosbuvir and ruzasvir for hepatitis C virus (HCV), and preclinical data for AT-587, their lead clinical candidate for hepatitis E virus (HEV). These presentations underscore Atea’s ongoing progress in its antiviral pipeline and its commitment to advancing new treatment options for patients with viral hepatitis.
Atea Pharmaceuticals Q1 2026 Earnings Call: Complete Transcript
Atea Pharmaceuticals reported a strong financial position with $256 million in cash and equivalents, projecting a cash runway through 2027. The company is progressing with its global Phase 3 HCV program, anticipating top-line data releases mid-year and year-end, and has expanded its pipeline to include a new HEV program, planning to initiate a first-in-human study mid-year. Management also highlighted a potential best-in-class profile for its HCV regimen, aiming for a strong position in the $2.6 billion global HCV market.
Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Q1 2026 Earnings Call Transcript
Atea Pharmaceuticals (NASDAQ: AVIR) held its Q1 2026 earnings call, detailing significant progress in its Hepatitis C (HCV) and Hepatitis E (HEV) programs. The company expects top-line data from its pivotal Phase 3 C-BEYOND HCV trial by mid-2026 and from the C-FORWARD trial by year-end, with over 95% enrollment completed for the latter. Atea also plans to initiate a first-in-human study for AT-587, its HEV product candidate, mid-year, aiming to address the unmet medical need for immunocompromised patients with chronic HEV infection, leveraging a strong financial position with $256 million in cash and marketable securities and a projected cash runway through 2027.
Atea Pharmaceuticals Announces Three Accepted Abstracts for Presentation at EASL Congress 2026
Atea Pharmaceuticals announced that three abstracts have been accepted for presentation at the EASL Congress 2026, scheduled from May 27-30 in Barcelona, Spain. The presentations will highlight advancements in hepatitis treatments, including data on their fixed-dose combination of bemnifosbuvir and ruzasvir for hepatitis C virus, and preclinical data for AT-587, a lead candidate for treating hepatitis E virus. CEO Dr. Jean-Pierre Sommadossi emphasized the importance of these therapies, especially for immunocompromised patients with chronic HEV, as the company prepares for Phase 3 trial results for HCV.
Atea Pharmaceuticals to Present Three Abstracts at EASL
Atea Pharmaceuticals (Nasdaq: AVIR) announced that three abstracts have been accepted for presentation at the European Association for the Study of the Liver (EASL) Congress 2026. The presentations will highlight progress across its viral hepatitis pipeline, including data for a fixed-dose combination regimen for hepatitis C virus (HCV) and preclinical data for AT-587, a lead clinical candidate for hepatitis E virus (HEV). The company expects these presentations to reinforce the potential of their treatments for HCV and HEV.
Earnings call transcript: Atea Pharmaceuticals Q1 2026 reports slight EPS miss, stock dips
Atea Pharmaceuticals reported a slight EPS miss for Q1 2026, with an EPS of -0.57 against a forecast of -0.56, leading to a 3.88% stock dip in after-hours trading. Despite this, the company maintains a strong cash position of $256 million, extending its runway through 2027, and is focused on advancing its Hepatitis C (HCV) and Hepatitis E (HEV) programs with two pivotal Phase III HCV data readouts expected in mid-2026 and year-end. The company emphasizes its financial discipline and strategic pipeline development, including preparations for potential commercial launches, while acknowledging regulatory and competitive challenges.
Atea Pharmaceuticals Q1 2026 Earnings Call: Complete Transcript
Atea Pharmaceuticals reported a strong financial position with $256 million in cash and equivalents, projecting a cash runway through 2027. The company is progressing with its global Phase 3 HCV program, having completed enrollment in North America and nearing completion outside North America, with anticipated top-line data releases mid-year and year-end. Atea Pharmaceuticals expanded its pipeline to include a new HEV program, planning to initiate a first-in-human study mid-year, targeting an unmet need in immunocompromised patients.
Earnings call transcript: Atea Pharmaceuticals Q1 2026 reports slight EPS miss, stock dips
Atea Pharmaceuticals reported a slight EPS miss for Q1 2026, with an EPS of -0.57 against a forecast of -0.56, leading to a 3.88% stock dip in after-hours trading. Despite this, the company highlighted a strong cash position of $256 million, extending its cash runway through 2027, and remains focused on advancing its Hepatitis C (HCV) and Hepatitis E (HEV) clinical programs, with key Phase III data readouts expected mid-year and year-end 2026 for HCV. The company emphasizes its potential for a best-in-class HCV treatment and addresses unmet medical needs in HEV, aiming for a capital-efficient commercial launch post-regulatory approval.
Atea Pharmaceuticals reports Q1 2026 net loss $45.4M, cash & marketable securities $256.0M
Atea Pharmaceuticals reported a Q1 2026 net loss of $45.4 million, an increase from Q1 2025, with cash and marketable securities totaling $256.0 million. The company's operating expenses rose to $48.0 million, primarily due to increased R&D investments in its HCV Phase 3 and HEV programs. Key milestones include expected topline results for its HCV C-BEYOND trial in mid-2026 and C-FORWARD trial around year-end 2026, alongside plans for HEV Phase 1 initiation.
[10-Q] Atea Pharmaceuticals, Inc. Quarterly Earnings Report
Atea Pharmaceuticals reported a widened net loss of $45.4 million in Q1 2026, compared to $34.3 million in Q1 2025, primarily due to increased investment in its late-stage antiviral programs, particularly Phase 3 hepatitis C trials and hepatitis E preclinical work. Despite this, the company ended the quarter with $256.0 million in cash, cash equivalents, and marketable securities, which it expects will fund operations through 2027. Atea is focused on advancing its HCV treatment regimen (bemnifosbuvir and ruzasvir) with topline Phase 3 results expected in mid-2026 and year-end 2026, and is also progressing AT-587 for hepatitis E into Phase 1 studies.
Atea Pharmaceuticals : Q1 26 IR Slide Deck 5 12 26 FINAL
Atea Pharmaceuticals released its Q1 2026 IR Slide Deck, providing updates on its antiviral pipeline. The company is advancing its Phase 3 program for Hepatitis C Virus (HCV) with its BEM/RZR regimen, expecting topline results in mid-2026 and year-end 2026, respectively, for its C-BEYOND and C-FORWARD trials. Additionally, Atea is progressing its AT-587 program for Hepatitis E Virus (HEV), targeting Phase 1 initiation mid-2026 and anticipating a significant commercial opportunity given the unmet medical need.
[8-K] Atea Pharmaceuticals, Inc. Reports Material Event
Atea Pharmaceuticals (NASDAQ: AVIR) reported a wider net loss of $45.4 million for Q1 2026, or $(0.57) per share, compared to $34.3 million (or $(0.40) per share) in Q1 2025. This was primarily due to increased R&D spending on its late-stage antiviral pipeline, including Phase 3 HCV trials and HEV preclinical development. The company ended the quarter with $256.0 million in cash and highlighted anticipated topline results for its HCV programs (C-BEYOND and C-FORWARD) and the planned initiation of a Phase 1 trial for its HEV candidate, AT-587, in mid-2026.
Boston biotech lines up 2026 trials for new hepatitis C and E drugs
Atea Pharmaceuticals reported its Q1 2026 financial results, showing a widened net loss of $45.4 million and cash reserves of $256.0 million. Despite the financial decline, the company is advancing its Phase 3 trials for Hepatitis C (HCV) drugs (C-BEYOND and C-FORWARD) with topline data expected mid-to-year-end 2026, and plans to initiate Phase 1 trials for its Hepatitis E Virus (HEV) candidate, AT-587, by mid-2026. The market reacted negatively to the news, with AVIR stock declining by 5.27%.
Atea Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update
Atea Pharmaceuticals reported its first-quarter 2026 financial results, highlighting significant progress in its Hepatitis C Virus (HCV) and Hepatitis E Virus (HEV) programs. The company expects topline results for its C-BEYOND Phase 3 North American HCV trial by mid-2026 and for its C-FORWARD trial around year-end 2026. Additionally, Atea plans to initiate a Phase 1 clinical program for AT-587, a potential first-in-class therapy for HEV, by mid-2026, addressing a critical unmet medical need.
TradingKey
This page provides an overview of Atea Pharmaceuticals Inc. (AVIR) stock, including its current price, market cap, and links to financial data, discussions, and analysis. It is part of the TradingKey platform, which offers various financial tools and information.
Atea Pharmaceuticals to Host First Quarter 2026 Financial Results and Business Update ...
Atea Pharmaceuticals, Inc. announced it will host a conference call and audio webcast on Tuesday, May 12, 2026, at 4:30 p.m. ET. The purpose of the call is to report financial results for the first quarter ended March 31, 2026, and to provide a business update. Atea is a late-stage clinical biopharmaceutical company focusing on developing oral antiviral therapeutics for serious viral diseases.
[SCHEDULE 13G/A] Atea Pharmaceuticals, Inc. Amended Passive Investment Disclosure
FMR LLC has filed an amended passive investment disclosure (SCHEDULE 13G/A) for Atea Pharmaceuticals, Inc. (AVIR), reporting beneficial ownership of 15.0% of the company's common stock, totaling 11,950,771.87 shares as of March 31, 2026. The filing indicates FMR LLC has sole dispositive power over these shares, with specific details regarding voting power and an 8.2% interest held by Fidelity Growth Company Commingled Pool within this total. This regulatory update signifies a substantial, yet passive, holding by FMR LLC in Atea Pharmaceuticals.
AVIR | Atea Pharmaceuticals, Inc. Common Insider Trading
This article provides an overview of insider trading activity for Atea Pharmaceuticals, Inc. (AVIR), along with other financial data such as institutional holdings, corporate lobbying expenditures, and U.S. patent grants. It notes the absence of recent insider trading activity from directors and management, and congressional trading data for this ticker. The piece also details corporate lobbying efforts primarily focused on health issues and medical research.
Atea sets May 12 webcast for quarterly results and business update
Atea Pharmaceuticals (Nasdaq: AVIR) will host a live conference call and audio webcast on May 12, 2026, at 4:30 p.m. ET to announce its first-quarter 2026 financial results and provide a business update. The webcast will be archived on the company's investor site for at least 90 days following the event. Investors can access the call via phone or webcast, with details provided for registration and dial-in.
Atea Pharmaceuticals to Host First Quarter 2026 Financial Results and Business Update Conference Call on May 12, 2026
Atea Pharmaceuticals announced it will host a conference call and audio webcast on Tuesday, May 12, 2026, at 4:30 p.m. ET. The call will cover the company's financial results for the first quarter ended March 31, 2026, and provide a business update. Interested participants can register online or access the live audio webcast through the Investor Relations section of Atea Pharmaceuticals' website.
Atea Pharmaceuticals (AVIR) price target increased by 25.00% to 10.20
This article reports that the price target for Atea Pharmaceuticals (AVIR) has been increased by 25.00% to $10.20. The content provided is minimal, only stating the title and this financial adjustment.
Atea Pharmaceuticals (AVIR) price target increased by 25.00% to 10.20
The price target for Atea Pharmaceuticals (AVIR) has been increased by 25.00% to $10.20. This adjustment indicates a more optimistic outlook on the company's stock performance.
Atea Pharmaceuticals (AVIR) price target increased by 25.00% to 10.20
This article reports that the price target for Atea Pharmaceuticals (AVIR) has been increased by 25.00%, raising it to $10.20. It's concise and focuses solely on this financial adjustment.
Atea Pharmaceuticals (NASDAQ: AVIR) sets 2026 proxy votes and outlines late-stage HCV strategy
Atea Pharmaceuticals (NASDAQ: AVIR) has released its definitive proxy statement for the 2026 annual meeting, detailing proposals for stockholder votes and outlining its strategic focus on late-stage Hepatitis C virus (HCV) and Hepatitis E virus (HEV) therapeutics. Key items for the annual meeting include the election of three Class III directors, ratification of KPMG LLP as the independent auditor, and an advisory vote on executive compensation. The company also highlighted progress in its Phase 3 HCV program, with topline data expected mid-to-late 2026, and announced the upcoming Phase 1 initiation for its HEV candidate, AT-587.
AVIR Technical Analysis & Stock Price Forecast
The article provides a technical analysis and stock price forecast for Atea Pharmaceuticals Inc (AVIR), indicating a "Strong Buy" consensus based on various technical indicators and moving averages. It details specific metrics like MACD, RSI, and support/resistance levels, alongside performance relative to its moving averages. The analysis suggests a bullish outlook for AVIR based on current market data.
Atea Pharmaceuticals (AVIR) price target increased by 33.33% to 8.16
Atea Pharmaceuticals (AVIR) has seen its price target increased by 33.33% to $8.16. This adjustment reflects a significant positive outlook on the company's stock valuation.
Atea Pharmaceuticals (AVIR) price target increased by 33.33% to 8.16
This article reports that the price target for Atea Pharmaceuticals (AVIR) has been increased by 33.33% to $8.16. Further details are not available in the provided text.
Vanguard disaggregation leaves Atea stake at 0% (NYSE: AVIR)
The Vanguard Group has filed an amended Schedule 13G/A indicating that its beneficial ownership of Atea Pharmaceuticals (AVIR) common stock is now 0 shares and 0% of the class. This change is due to an internal realignment within Vanguard, where certain subsidiaries will now report their holdings separately in accordance with SEC Release No. 34-39538. The filing clarifies that this disaggregation is an administrative change in reporting structure and does not represent a sale or purchase of Atea's securities.
If You Invested $1,000 in Atea Pharmaceuticals, Inc. (AVIR)
This article analyzes the historical performance of investing $1,000 in Atea Pharmaceuticals, Inc. (AVIR) over various timeframes, comparing its returns to the S&P 500. It highlights that a $1,000 investment made 10 years ago would now be worth $297, underperforming the S&P 500 significantly. The article also provides a detailed overview of Atea Pharmaceuticals, Inc., its focus on oral antiviral therapies for serious viral infections like HCV and HEV, and its clinical development programs for bemnifosbuvir/ruzasvir regimen.
Top 2 Health Care Stocks That May Fall Off A Cliff This Month
As of March 18, 2026, Arcellx Inc. (NASDAQ: ACLX) and Atea Pharmaceuticals Inc. (NASDAQ: AVIR) are identified as overbought health care stocks, potentially signaling a warning to momentum-focused investors. Both companies have seen significant stock gains recently, with their Relative Strength Index (RSI) values well above the overbought threshold of 70, indicating they might be due for a pullback. Gilead Sciences' acquisition of Arcellx and an analyst upgrade for Atea Pharmaceuticals have contributed to their recent surges.
Atea Pharmaceuticals (NASDAQ: AVIR) officer exercises options for 60,000 shares
Atea Pharmaceuticals' officer Andrea Corcoran exercised stock options to acquire 60,000 shares of common stock at $1.24 per share, a routine compensation event. Following this transaction, her direct holdings in Atea common stock increased to 823,576 shares, with no reported same-day sales. This exercise-and-hold pattern is seen as an alignment of compensation with equity.
Atea Pharmaceuticals (NASDAQ:AVIR) Hits New 12-Month High - Here's Why
Shares of Atea Pharmaceuticals (NASDAQ:AVIR) reached a new 52-week high of $6.39 on Tuesday. This rise comes despite mixed analyst sentiment, with a consensus "Hold" rating and a target price of $6.00, and a recent EPS miss. The company, a clinical-stage antiviral developer, has seen increased institutional ownership.
Atea Pharmaceuticals (AVIR) Price Target Raised by Evercore ISI
Evercore ISI Group has maintained its "Outperform" rating on Atea Pharmaceuticals (AVIR) and significantly raised its price target from $6.00 to $10.00. This 66.67% increase reflects the firm's enhanced confidence in the company's future. Atea Pharmaceuticals is a clinical-stage biopharmaceutical company focused on antiviral therapeutics, with product candidates for COVID-19 and Hepatitis C.
Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Atea Pharmaceuticals reported its fourth-quarter and full-year 2025 financial results, highlighting progress in its global Phase 3 program for Hepatitis C Virus (HCV) and the expansion of its antiviral pipeline to include a Hepatitis E Virus (HEV) program. The company expects topline results from its North American HCV trial (C-BEYOND) in mid-2026 and from the C-FORWARD trial outside North America by year-end 2026. Atea also emphasized the potential of its bemnifosbuvir/ruzasvir regimen as a best-in-class HCV treatment and announced the lead HEV candidate, AT-587, is expected to enter clinical development mid-2026.
Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Q4 2025 Earnings Call Transcript
Atea Pharmaceuticals (NASDAQ:AVIR) held its Q4 2025 earnings call, reporting an EPS miss but highlighting significant clinical progress. The company is advancing its global Phase III program for HCV treatment with bemnifosbuvir and ruzasvir, expecting top-line readouts for both C-BEYOND and C-FORWARD trials this year. Atea also expanded its pipeline into chronic hepatitis E (HEV) with lead candidate AT-587, citing a strong financial position to fund both programs through 2027.
New hepatitis antivirals: inside Atea’s 2026 HCV and HEV trial plans
Atea Pharmaceuticals reported its Q4 and full-year 2025 financial results, including a net loss of $158.3 million and cash/investments of $301.8 million. The company announced the completion of enrollment for its C-BEYOND Phase 3 HCV trial with topline results expected mid-2026, and anticipates C-FORWARD results around year-end 2026. Additionally, Atea plans to initiate clinical development for AT-587, its lead candidate for hepatitis E virus (HEV), in mid-2026.
Earnings call transcript: Atea Pharmaceuticals Q4 2025 sees stock rise despite EPS miss
Atea Pharmaceuticals reported a Q4 2025 EPS of -0.57, missing analyst estimates, but its stock rose 6.43% in aftermarket trading, suggesting investor optimism driven by strong cash reserves and positive clinical trial results for its HCV program. The company expects to extend its cash runway through 2027 and anticipates profitability after launching its HCV treatment, with ongoing clinical trials for both HCV and a new HEV program.
Insights Ahead: Atea Pharmaceuticals's Quarterly Earnings
Atea Pharmaceuticals (NASDAQ: AVIR) is set to release its quarterly earnings report on Thursday, March 5, 2026, with analysts anticipating an EPS of $-0.48. The company's past performance shows that missing EPS estimates has led to share price drops, while shares have risen 63.0% over the last 52 weeks. Investors are optimistic for positive guidance in the upcoming report.
Atea Pharmaceuticals Q4 Earnings Call Highlights
Atea Pharmaceuticals provided progress updates on its Phase 3 Hepatitis C Virus (HCV) program and expanded Hepatitis E Virus (HEV) pipeline during its Q4 2025 earnings call. The company expects top-line readouts for its HCV trials in 2026 and selected AT-587 as its lead HEV candidate, planning first-in-human studies by mid-2026. Atea also reported $301.8 million in cash reserves, projecting a financial runway through 2027, and outlined its commercial strategy for HCV.
Atea Pharmaceuticals 10-K: $0 Revenue, $(158.3)M Net Loss
Atea Pharmaceuticals reported $0 revenue and a net loss of $(158.3) million for the year ended December 31, 2025, as it has no FDA-approved products. The company has $301.8 million in cash and expects these funds to support operations through 2027 while it advances late-stage clinical programs, including its Phase 3 hepatitis C programs and a planned FDA NDA submission in March 2027. Atea also implemented a 25% workforce reduction in Q1 2025 for efficiency.
Atea Pharmaceuticals (NASDAQ:AVIR) Posts Earnings Results, Misses Expectations By $0.08 EPS
Atea Pharmaceuticals (NASDAQ:AVIR) reported quarterly earnings of ($0.57) per share, missing consensus estimates by $0.08. Despite the earnings miss, shares rose by $0.32 to $5.30, nearing its 12-month high. Institutional investors hold a significant portion of the stock, and analysts currently have a "Moderate Buy" rating with a $6.00 price target.
Atea Pharmaceuticals (Nasdaq: AVIR) narrows 2025 loss and advances HCV, HEV pipeline
Atea Pharmaceuticals reported a narrower net loss of $158.3 million in 2025, down from $168.4 million in 2024, despite continued investment in its hepatitis portfolio. The company advanced its global Phase 3 HCV program with topline results expected in 2026 and expanded into hepatitis E with lead candidate AT-587, slated for clinical development in mid-2026. Cash reserves stood at $301.8 million at the end of 2025, supporting ongoing R&D efforts.
Insights Ahead: Atea Pharmaceuticals's Quarterly Earnings
Atea Pharmaceuticals (NASDAQ: AVIR) is set to release its quarterly earnings report on Thursday, 2026-03-05. Analysts estimate an EPS of $-0.48. The company's past performance shows a share price drop of 12.57% after missing EPS estimates in the previous quarter, but its shares have risen 63.0% over the last 52 weeks.
Atea Pharmaceuticals (NASDAQ: AVIR) outlines late-stage HCV Phase 3 plans
Atea Pharmaceuticals (NASDAQ: AVIR) is advancing its late-stage Hepatitis C Virus (HCV) program, with topline results for its C-BEYOND Phase 3 trial expected mid-2026 and C-FORWARD trial by year-end 2026, targeting a US NDA submission in March 2027. The company is also developing AT-587 for chronic Hepatitis E Virus (HEV), with a first-in-human Phase 1 study planned for mid-2026. Atea has discontinued its COVID-19 program after its Phase 3 SUNRISE-3 trial did not meet its primary endpoint in 2024.
